If you represent or support a pharmaceutical manufacturer, chances are good you’ve seen all the conversation around biosimilars heating up. In July alone, we saw an unprecedented number (seven!) of biosimilars for Humira launch simultaneously. Interestingly, though, if you look at the conversation going on in the marketplace, the bulk of the discussion about which will be adopted and why is focused on behind-the-scenes pricing. However, as many recent reports and our experience indicate, that’s not really what’s standing in the way of adoption.

The survey of 502 employers by Accolade, a company that provides healthcare programs for employers, and research firm Savanta said 43% of the employers it polled could cover GLP-1 drugs in 2024 compared to 25% that cover them now.